Searching across hundreds of databases
Medulloblastoma (MB) is the most common malignant brain tumor in children and requires intensive multimodal therapy. Long-term survival is still dissatisfying and, most importantly, survivors frequently suffer from severe treatment-associated morbidities. The sonic hedgehog pathway (SHH) in SHH MB provides a promising target for specific therapeutic agents. The small molecule Vismodegib allosterically inhibits SMO, the main upstream activator of SHH. Vismodegib has proven effective in the treatment of MB in mice and in clinical studies. However, due to irreversible premature epiphyseal growth plate fusions after systemic application to infant mice and children, its implementation to pediatric patients has been limited. Intraventricular Vismodegib application might provide a promising novel treatment strategy for pediatric medulloblastoma patients.
Pubmed ID: 37767814 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets sox2
View all literature mentionsThis monoclonal targets Phospho-Histone H3 (Ser10)
View all literature mentionsThis polyclonal targets Oligodendrocute transcription factor 2
View all literature mentionsThis monoclonal targets N-Myc
View all literature mentionsThis monoclonal targets Neuronal Nuclei
View all literature mentionsThis polyclonal targets Ki67 antibody - Proliferation Marker
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis polyclonal targets Iba1
View all literature mentionsThis unknown targets Cre Recombinase
View all literature mentionsThis monoclonal targets CD3 antibody [SP7]
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
